/
ELVN
$50.85+$0.77 (+1.54%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$3.6B
71M shares
52-week range
$14.79 – $51.06
99% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.73%
Moderate
Price (6 mo)
Loading chart…
Change+$27.10
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $33.0K | $0 | $0 | $0 | $0 | $0 | $263.0K |
| Gross profit | $0 | −$33.0K | $0 | $0 | $0 | $0 | $0 | −$263.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $8.2M | $19.0M | $8.2M | $20.5M | $31.0M | $64.6M | $80.8M | $85.9M |
| Operating income | −$10.7M | −$24.1M | −$9.3M | −$24.8M | −$38.8M | −$83.5M | −$104.6M | −$119.7M |
| EBITDA | −$11.3M | −$23.4M | −$9.3M | −$24.6M | −$37.4M | −$71.3M | −$88.5M | −$103.4M |
| Net income | −$11.3M | −$23.5M | −$19.0M | −$24.7M | −$37.7M | −$71.6M | −$89.0M | −$103.7M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -2.62 | -5.43 | -4.31 | -3.17 | -6.03 | -2.01 | -1.89 | -1.83 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10000 | $-1.77 | $-2.05–$-1.42 | 5 |
| 2027 | $7143 | $-2.40 | $-2.88–$-1.93 | 4 |
| 2028 | $16667 | $-2.98 | $-3.60–$-1.95 | 7 |
| 2029 | $73M | $-2.79 | $-2.79–$-2.79 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.70
Price
$50.85
Implied downside
-97%
Peer comparison
Enliven Therapeutics, Inc. Common Stock
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
www.enliventherapeutics.com- Employees
- 61
- IPO / List date
- Feb 24, 2023
- HQ
- BOULDER, CO
Held by traders on TradeandTell
No one on the platform currently holds ELVN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 59,000 | $1.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ELVN yet.
